Cell division

Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China

Retrieved on: 
Monday, October 4, 2021
Mortality, Cell death, Pancreatic cancer, Cytoplasm, Private Securities Litigation Reform Act, Overalls, Chromosome, Mesothelioma, Cell, Safety, Investment, Capecitabine, Protein, Glioblastoma, Microtubule, Degenerative disease, Health, U.S. Securities and Exchange Commission, LinkedIn, Adult, Infection, Twitter, Coronavirus, Ovarian cancer, Cell division, Survival, Incidence, EDGAR, Clinical trial, Mitosis, Annual report, NASDAQ, Cancer, Neoplasm, Toxicity, Alternating electric field therapy, Stomach, Large-cell lung carcinoma, Stomach cancer, HIV disease progression rates, Forward-looking statement, GLOBE, Oxaliplatin, Fundamental, Risk, Patient, XELOX, Liver cancer, COVID-19, Drug development, Data collection, Skin, Pharmaceutical industry, Medical imaging

SHANGHAI and St. Helier, JERSEY, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, today announced that the final patient has been enrolled in a Novocure-sponsored phase 2 pilot trial conducted by Zai Lab evaluating the safety and efficacy of Tumor Treating Fields (TTFields) in combination with chemotherapy as a first-line treatment in patients with gastric adenocarcinoma. Final data collection is expected in the first half of 2022.

Key Points: 
  • This trial, conducted entirely in China, showcases Zais capabilities as we partner with Novocure to expand treatment options for gastric cancer patients in China.
  • The phase 2 pilot gastric cancer trial of TTFields has enrolled approximately 30 patients in Greater China.
  • We look forward to seeing results from this phase 2 pilot trial with our partner, Zai Lab, and to further exploring the potential of Tumor Treating Fields as a treatment for gastric cancer.
  • Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China

Retrieved on: 
Monday, October 4, 2021
Oncology, Health, Clinical Trials, General Health, Radiology, Biotechnology, Mortality, Glioblastoma, Clinical trial, Cell death, Microtubule, Oxaliplatin, Degenerative disease, Mitosis, Pancreatic cancer, Risk, Cytoplasm, Annual report, Health, Private Securities Litigation Reform Act, NASDAQ, Overalls, U.S. Securities and Exchange Commission, Cancer, Patient, Neoplasm, XELOX, LinkedIn, Adult, Liver cancer, Stomach, Chromosome, Infection, Toxicity, Twitter, Coronavirus, Alternating electric field therapy, Ovarian cancer, Large-cell lung carcinoma, Cell division, Mesothelioma, Stomach cancer, Fundamental, COVID-19, HIV disease progression rates, Drug development, Survival, Safety, Incidence, Cell, Investment, Forward-looking statement, Capecitabine, Data collection, Skin, Protein, Pharmaceutical industry, Medical imaging, Gastric Cancer, Tumor Treating Fields, Novocure, Zai Lab, GASTRIC CANCER, TUMOR TREATING FIELDS, NOVOCURE, ZAI LAB

This trial, conducted entirely in China, showcases Zais capabilities as we partner with Novocure to expand treatment options for gastric cancer patients in China.

Key Points: 
  • This trial, conducted entirely in China, showcases Zais capabilities as we partner with Novocure to expand treatment options for gastric cancer patients in China.
  • The phase 2 pilot gastric cancer trial of TTFields has enrolled approximately 30 patients in Greater China.
  • We look forward to seeing results from this phase 2 pilot trial with our partner, Zai Lab, and to further exploring the potential of Tumor Treating Fields as a treatment for gastric cancer.
  • Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Boundless Bio Announces Upcoming Presentation at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021

Retrieved on: 
Wednesday, September 22, 2021
Oncology, Health, Genetics, Clinical Trials, Research, Science, Biotechnology, Rolling circle replication, Cancer, Radiation, Dana–Farber Cancer Institute, Recurrence, Therapy, Conference, DNA, Dana, FDA, Patient, AACR, Bio, Immunotherapy, Cell division, Colorectal cancer, Survival, Oncogene, Pharmaceutical industry, Vaccine, ecDNA, Boundless Bio, ECDNA, BOUNDLESS BIO

Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced plans to present at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, held virtually from October 7-10, 2021.

Key Points: 
  • Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced plans to present at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, held virtually from October 7-10, 2021.
  • These findings support previous Boundless Bio published work that ecDNA is an important underlying cause of cancer resistance and reinforces the critical need for novel therapeutic strategies to address ecDNA enabled cancers.
  • ecDNA replicate within cancer cells and can be passed to daughter cells asymmetrically during cell division, thereby constituting a primary driver of focal gene amplification and copy number heterogeneity in cancer.
  • Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer

Retrieved on: 
Tuesday, September 14, 2021
Research, Medical Devices, FDA, Clinical Trials, Radiology, Health, Other Science, Science, Oncology, Pancreatic cancer, Chromosome, Ovarian cancer, Cell, ROG, Stomach, Private Securities Litigation Reform Act, Liver cancer, Forward-looking statement, Alternating electric field therapy, Fundamental, Protein, Patient, Microtubule, Neoplasm, RECIST, Cytoplasm, Glioblastoma, U.S. Securities and Exchange Commission, LinkedIn, Pancreas, Safety, Survival, Adult, Annual report, RO, NASDAQ, Toxicity, Skin, Large-cell lung carcinoma, COVID-19, Mitosis, Cell death, Twitter, Mesothelioma, Death, Cell division, PDAC, Cancer, PFS, Pharmaceutical industry, Medical imaging, Tumor Treating Fields, Novocure, TUMOR TREATING FIELDS, NOVOCURE

ROG; OTCQX: RHHBY), to develop Tumor Treating Fields (TTFields) together with Roches anti-PD-L1 therapy, atezolizumab, in metastatic pancreatic ductal adenocarcinoma (mPDAC).

Key Points: 
  • ROG; OTCQX: RHHBY), to develop Tumor Treating Fields (TTFields) together with Roches anti-PD-L1 therapy, atezolizumab, in metastatic pancreatic ductal adenocarcinoma (mPDAC).
  • Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and accounts for 85%95% of all solid pancreatic tumors.
  • Tumor Treating Fields, or TTFields, are electric fields that disrupt cancer cell division.
  • Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

CyTOF and Maxpar Direct Technologies Utilized in Study Characterizing Immune and Inflammatory Responses in Pregnant Women Infected with SARS-CoV-2

Retrieved on: 
Tuesday, August 31, 2021
Life, Gene, Knowledge, Biomarker, Social media, CyTOF, Research, Health, Infection, Risk, Plasma, COVID-19, Woman, Fetus, University, U.S. Securities and Exchange Commission, Immunosuppression, LDN (song), Doctor of Philosophy, Patent, Forward-looking statement, Regulation Fair Disclosure, Disclosure, LDN, MD, Industry, University of Modena and Reggio Emilia, Pregnancy, Quality of life, Twitter, Cell division, Severe acute respiratory syndrome coronavirus 2, Blood, Government, United, Disease, Immunotherapy, Biotechnology, NASDAQ, SAN, LinkedIn, Cytokine, Private Securities Litigation Reform Act, Cancer, GLOBE, Immune system, Physician, Microfluidics, Marketing, Inflammation, Regulation, Nature Communications, Patient, Annual report, Pharmaceutical industry, Birth control, Vaccine

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the publication of new data further validating the potential of its mass cytometry technologies, including CyTOF® systems and the Maxpar® Direct™ Immune Profiling Assay™, to enable deep profiling of immune and inflammatory responses that play critical roles in infection and other significant health conditions.

Key Points: 
  • The recently published study in Nature Communications evaluated key inflammatory pathways in pregnant women infected with SARS-CoV-2, the virus that causes COVID-19, compared with uninfected pregnant women and women who were not pregnant.
  • They provide clinicians with important insights for potential consideration in managing care for pregnant women infected with the virus.
  • Key findings of the study include:
    Evaluation of 62 cytokines in 14 infected pregnant women, 28 uninfected pregnant women and 15 age-matched women who were not pregnant (controls) found that pregnant women generally had more anti-inflammatory cytokine profiles compared with controls, and that this was increased in pregnant women who were infected.
  • Comprehensive analyses identified highly significant correlations between the levels of LDN and multiple cytokines in infected women but not in uninfected pregnant women.

Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Launched in Japan for EZH2 Gene Mutation-Positive Follicular Lymphoma

Retrieved on: 
Monday, August 16, 2021
Dysgeusia, Common, Phosphorylation, S-Adenosyl methionine, Cell division, Refractory, Lymphoma, Gene, Incidence, Eisai, Continuity, Science, Efficiency, Molecular Cancer Research, Research, DNA, Methylation, Nature Genetics, Genetics, Ageing, American Association for Cancer Research, Therapy, Diffuse large B-cell lymphoma, ORR, Automation, Carcinogenesis, Acetylation, Mutation, Review, Follicular lymphoma, EZH2, Advanced manufacturing, Safety, Adult, Blood, Patient, Lymphocytopenia, Relapse, Neoplasm, FDA, Veni, vidi, vici, Histone, Technology, Gene expression, Vaccine, Fine chemical, Pharmaceutical industry, Wood drying

This agent selectively inhibits EZH2 in a competitive matter with S-adenosylmethionine (a methyl group donor) to suppress methylation of H3K27.

Key Points: 
  • This agent selectively inhibits EZH2 in a competitive matter with S-adenosylmethionine (a methyl group donor) to suppress methylation of H3K27.
  • Eisai was one of the first to adopt Continuous Manufacturing system (CTS-MiGRA) and applied this technology to the production of this agent.
  • Study 206 enrolled patients with EZH2 gene mutation-positive, primarily follicular lymphoma, who had relapsed or were refractory.
  • Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin.

Genes necessary for cell division in modern bacterial cells identified

Retrieved on: 
Monday, March 29, 2021
Branches of biology, Biology, Cellular processes, Cytoskeleton, FtsZ, Cell division, Cell, Gene

Motivated by the striking differences between the normal cell division exhibited by JCVI-syn1.0 and the lack of cell division shown in time-lapse videos of the minimal cell growing in microfluidic chambers, the JCVI team began a long series of experiments to determine which genes would be necessary to restore normal cell division to JCVI-syn3.0.

Key Points: 
  • Motivated by the striking differences between the normal cell division exhibited by JCVI-syn1.0 and the lack of cell division shown in time-lapse videos of the minimal cell growing in microfluidic chambers, the JCVI team began a long series of experiments to determine which genes would be necessary to restore normal cell division to JCVI-syn3.0.
  • That set included two known cell division genes, ftsZ and sepF, plus 5 genes whose roles in the cell were completely unknown before this work.
  • JCVI-syn3.0 and JCVI-syn3A now provide a robust platform for investigating how modern cell division and cell size evolved.
  • The complete study, " Genetic requirements for cell division in a genomically minimal cell ," may be found in the journal Cell.